LifeMD, Inc.
NASDAQ:LFMDMedical - Pharmaceuticals
-$0.16 today
- Market cap
- $82.17M
- Beta
- 1.99
- P/E (TTM)
- -13.8
- EPS (TTM)
- -$0.34
Volume 0.80M
Average 1.04M
LFMD Net Income
Bottom-line profit, the starting point for calculating cash from operations.
LifeMD, Inc.NASDAQ: LFMD
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns negative
Q1 FY2026 net income was -$8.87M, compared with $1.92M a year earlier. Trailing-twelve-month net income was $507.37K.
Context
- Net income amounted to 8.0% of revenue in FY2025, down 0.8 pp from a year earlier.
- Net income increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 5 analysts of -$26.7M (-270.9%) for the fiscal year ending Dec 2026, a slowdown from the +183.4% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$8.87M-156.8% QoQ
- Last fiscal yearDec 2025
- $15.62M+183.4% YoY
- LTMMar 2026
- $507.37K+105.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -562.9% | +347.2% | +910.2 pp |
| 1 year | +183.4% | -270.9% | -454.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 15.62M USD
- Year-over-year change
- +183.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.62M | +183.4% |
| FY2024 | 2024-12-31 | (18.73M) | +9.1% |
| FY2023 | 2023-12-31 | (20.6M) | +54.3% |
| FY2022 | 2022-12-31 | (45.02M) | +26.6% |
| FY2021 | 2021-12-31 | (61.32M) | — |
Net Income vs competitors
How LFMD compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +105.0% is the 3rd highest of 10, against a peer median of +17.8%.
- Net income amounts to 0.2% of revenue for LFMD, versus a peer median of 41.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $87.19M USD | +17.8% | — | 214.2% | |
| LTM Mar 2026 | $52.66M USD | +2.2% | +8.8% | 89.1% | |
| LTM Apr 2026 | CA$46.43M CAD | +388.6% | -10.1% | 6.9% | |
| LTM Mar 2026 | $37.25M USD | -24.6% | -23.6% | 46.8% | |
| LTM Mar 2026 | $35.6M USD | +101.3% | — | 61.6% | |
| LTM Mar 2026 | $23.67M USD | +103.8% | +50.6% | 22.0% | |
| LTM Mar 2026 | $17.17M USD | -26.3% | -28.6% | 41.1% | |
| LTM Mar 2026 | $16.51M USD | +191.1% | -35.0% | 4.8% | |
| LTM Mar 2026 | $9.56M USD | -49.7% | -28.5% | 4.3% | |
| LTM Mar 2026 | $507.37K USD | +105.0% | — | 0.2% | |
| Peer median (excluding LFMD) | — | +17.8% | -23.6% | 41.1% | |
Competitors are the stored peer set for LFMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (61.32M) | (45.02M) | (20.6M) | (18.73M) | 15.62M |
| Depreciation & Amortization | 868.76K | 3.77M | 6.6M | 9.49M | 328.37K |
| Deferred Income Tax | 0 | 354K | 0 | 0 | 0 |
| Stock-Based Compensation | 12.07M | 13.73M | 12.49M | 12.23M | 10.5M |
| Change in Working Capital | 9.13M | (1.55M) | 4.91M | 12.65M | (7.85M) |
| Accounts Receivables | 17.7K | (2.19M) | (2.44M) | (2.94M) | 1.15M |
| Inventory | (409.82K) | (2.18M) | 764.33K | 675.67K | 303.24K |
| Accounts Payables | (893.96K) | 1.25M | 978.06K | 4.92M | 3.24M |
| Other Working Capital | 10.42M | 1.58M | 5.61M | 9.99M | (12.55M) |
| Other Non-Cash Items | 6.17M | 5.78M | 5.42M | 1.87M | (10.31M) |
| Operating Cash Flow | (33.09M) | (22.94M) | 8.82M | 17.51M | 8.28M |
| Capital Expenditures | (3.4M) | (12.89M) | (8.73M) | (11.54M) | (9.52M) |
| Acquisitions (Net) | 0 | (1.01M) | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (3.15M) | (12.53M) | (8.53M) | (10.05M) | 8.78M |
| Investing Cash Flow | (3.4M) | (13.91M) | (8.73M) | (11.54M) | 6.91M |
| Debt Repayment | (530.82K) | 2.74M | 16.67M | (327.6K) | (18.72M) |
| Common Stock Issued | 13.99M | 0 | 16.2M | 0 | 9.19M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (871.48K) | (3.11M) | (3.11M) | (3.11M) | (3.11M) |
| Other Financing Activities | 707.36K | (159.2K) | (667.63K) | (684.83K) | (773.66K) |
| Financing Cash Flow | 68.64M | (528.2K) | 29.1M | (4.12M) | (13.41M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 32.15M | (37.37M) | 29.19M | 1.86M | 1.78M |
| Free Cash Flow | (36.49M) | (35.83M) | 86.95K | 5.98M | (1.24M) |
LifeMD, Inc.
NASDAQ:LFMD
Intrinsic Alpha fair value
Locked
Current Price
$1.70
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.